Literature DB >> 8395068

Isozyme-selective cyclic nucleotide phosphodiesterase inhibitors: biochemistry, pharmacology and therapeutic potential in asthma.

D Raeburn1, J E Souness, A Tomkinson, J A Karlsson.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8395068     DOI： 10.1007/978-3-0348-7147-1_3

Source DB:  PubMed          Journal:  Prog Drug Res        ISSN： 0071-786X


× No keyword cloud information.
  10 in total

1.  The effect of isoenzyme-selective PDE inhibitors on methacholine-induced contraction of guinea-pig and rat ileum.

Authors:  A Tomkinson; D Raeburn
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

2.  Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen.

Authors:  P G Bardin; M A Dorward; F C Lampe; B Franke; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 3.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

4.  Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.

Authors:  L Pooley; Y Shakur; G Rena; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

5.  Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone.

Authors:  J E Souness; M E Villamil; L C Scott; A Tomkinson; M A Giembycz; D Raeburn
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

6.  Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.

Authors:  J E Souness; C Maslen; S Webber; M Foster; D Raeburn; M N Palfreyman; M J Ashton; J A Karlsson
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

7.  Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors.

Authors:  J Van Wauwe; F Aerts; H Walter; M de Boer
Journal:  Inflamm Res       Date:  1995-09       Impact factor: 4.575

8.  Phosphodiesterase V inhibition reduces airway responsiveness, but does not improve the beneficial effect of deep inspiration.

Authors:  George Pyrgos; Alkis Togias; Robert H Brown
Journal:  Respiration       Date:  2013-07-16       Impact factor: 3.580

9.  Changes in A-type natriuretic peptide and its receptors induced by a neutral endopeptidase inhibitor in a rat model of sepsis.

Authors:  Kanetaka Maeshiro; Shinzo Takamori; Hiroharu Mifune; Toshihiro Matsuo; Norman Y Kimura; Junichi Honda; Kazuo Shirouzu
Journal:  Surg Today       Date:  2008-02-01       Impact factor: 2.549

10.  Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor.

Authors:  D Raeburn; S L Underwood; S A Lewis; V R Woodman; C H Battram; A Tomkinson; S Sharma; R Jordan; J E Souness; S E Webber
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.